Downregulation of telomerase maintenance-related ACD expression in patients undergoing immunosuppresive therapy following kidney transplantation

Witkowska,Agnieszka; Strzalka‑Mrozik,Barbara; Owczarek,Aleksander; Gola,Joanna; Mazurek,Urszula; Grzeszczak,Wladyslaw; Gumprecht,Janusz

doi:10.3892/etm.2015.2785

Downregulation of telomerase maintenance-related ACD expression in patients undergoing immunosuppresive therapy following kidney transplantation

Authors:
- Agnieszka Witkowska
- Barbara Strzalka‑Mrozik
- Aleksander Owczarek
- Joanna Gola
- Urszula Mazurek
- Wladyslaw Grzeszczak
- Janusz Gumprecht
View Affiliations

Affiliations: Department of Internal Medicine, Diabetology and Nephrology, Medical University of Silesia, 41‑800 Zabrze, Silesia, Poland, Department of Molecular Biology, Medical University of Silesia, 41‑200 Sosnowiec, Silesia, Poland, Division of Statistics, Medical University of Silesia, 41‑200 Sosnowiec, Silesia, Poland
Published online on: October 2, 2015 https://doi.org/10.3892/etm.2015.2785
Pages: 2224-2230

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic administration of immunosuppressants has been associated with long-term consequences, including a higher risk of neoplasm development. The processes regulating telomere function exert a major influence on human cancer biology. The present study aimed to assess the effect of immunosuppressive therapy on the expression of genes associated with telomere maintenance and protection in patients following renal transplantation. A total of 51 patients that had undergone kidney transplantation and 54 healthy controls were enrolled in the study. The 51 transplant patients received a three‑drug immunosuppressive regimen consisting of cyclosporine A, prednisone and mycophenolate mofetil. In stage 1 of the study, the expression profiles of 123 transcripts, which represented 70 genes, were assessed in peripheral mononuclear blood cells using an oligonucleotide microarray technique in 8 transplant recipients and 4 healthy control subjects. Among the analyzed transcripts, the expression levels of 4 differed significantly between the studied groups; however, only the ACD (adrenocortical dysplasia homolog) gene, encoding the telomere‑binding protein POT1‑interacting protein 1 (TPP1), was sufficiently specific for telomere homeostasis. The expression of ACD was downregulated in transplant recipients (fold change, 2.11; P=0.006). In stage 2 of the study, reverse transcription‑quantitative polymerase chain reaction analysis of ACD, DKC1 and hTERT mRNA was conducted for all transplant patients and control subjects. The results confirmed the downregulation of the ACD gene in patients that had received immunosuppressive therapy (P=0.002). The results of the present study indicate that the downregulation of ACD gene transcription, and thus TPP1 protein expression, may enhance the capacity for cell immortalization, despite normal levels of other key telomere maintenance factors, in patients undergoing immunosuppressive therapy. Furthermore, the results indicate that TPP1 has potential for use as an early clinical marker and/or therapeutic target for cancer in patients following organ transplantation.

View Figures

View References

1	Alberú J: Clinical insights for cancer outcomes in renal transplant patients. Transplant Proc. 42(9 Suppl): S36–S40. 2010. View Article : Google Scholar : PubMed/NCBI
2	Briggs JD: Causes of death after renal transplantation. Nephrol Dial Transplant. 16:1545–1549. 2001. View Article : Google Scholar : PubMed/NCBI
3	Kasiske BL, Snyder JJ, Gilbertson DT and Wang C: Cancer after kidney transplantation in the United States. Am J Transplant. 4:905–913. 2004. View Article : Google Scholar : PubMed/NCBI
4	First MR and Peddi VR: Malignancies complicating organ transplantation. Transplant Proc. 30:2768–2770. 1998. View Article : Google Scholar : PubMed/NCBI
5	Maser RS and DePinho RA: Connecting chromosomes, crisis and cancer. Science. 297:565–569. 2002. View Article : Google Scholar : PubMed/NCBI
6	Cheung AL and Deng W: Telomere dysfunction, genome instability and cancer. Front Biosci. 13:2075–2090. 2008. View Article : Google Scholar : PubMed/NCBI
7	Grady WM: Genomic instability and colon cancer. Cancer Metastasis Rev. 23:11–27. 2004. View Article : Google Scholar : PubMed/NCBI
8	de Lange T: Shelterin: The protein complex that shapes and safeguards human telomeres. Genes Dev. 19:2100–2110. 2005. View Article : Google Scholar : PubMed/NCBI
9	Martínez P and Blasco MA: Role of shelterin in cancer and aging. Aging Cell. 9:653–666. 2010. View Article : Google Scholar : PubMed/NCBI
10	Lu W, Zhang Y, Liu D, Songyang Z and Wan M: Telomeres-structure, function and regulation. Exp Cell Res. 319:133–141. 2013. View Article : Google Scholar : PubMed/NCBI
11	Artandi SE and DePinho RA: Telomeres and telomerase in cancer. Carcinogenesis. 31:9–18. 2010. View Article : Google Scholar : PubMed/NCBI
12	Kong CM, Lee XW and Wang X: Telomere shortening in human diseases. Febs J. 280:3180–3193. 2013. View Article : Google Scholar : PubMed/NCBI
13	DePinho RA and Polyak K: Cancer chromosomes in crisis. Nat Genet. 36:932–934. 2004. View Article : Google Scholar : PubMed/NCBI
14	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
15	Harley CB, Futcher AB and Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature. 345:458–460. 1990. View Article : Google Scholar : PubMed/NCBI
16	Wenz C, Enenkel B, Amacker M, Kelleher C, Damm K and Lingner J: Human telomerase contains two cooperating telomerase RNA molecules. Embo J. 20:3526–3534. 2001. View Article : Google Scholar : PubMed/NCBI
17	Mergny JL, Riou JF, Mailliet P, Teulade-Fichou MP and Gilson E: Natural and pharmacological regulation of telomerase. Nucleic Acids Res. 30:839–865. 2002. View Article : Google Scholar : PubMed/NCBI
18	Kim NW, Piatyszek MA, Prowse KR, et al: Specific association of human telomerase activity with immortal cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
19	Hiyama E and Hiyama K: Telomerase as tumor marker. Cancer Lett. 194:221–233. 2003. View Article : Google Scholar : PubMed/NCBI
20	Calado R and Young N: Telomeres in disease. F1000 Med Rep. 4:82012.PubMed/NCBI
21	Witkowska A, Gumprecht J, Glogowska-Ligus J, et al: Expression profile of significant immortalization genes in colon cancer. Int J Mol Med. 25:321–329. 2010. View Article : Google Scholar : PubMed/NCBI
22	Rostkowska-Nadolska B, Kapral M, Fraczek M, Kowalczyk M, Gawron W and Mazurek U: Transcriptional activity of genes-encoding kinin B1 and B2 receptors and kinin-dependent genes in nasal polyps. Adv Med Sci. 54:211–220. 2009. View Article : Google Scholar : PubMed/NCBI
23	Strzalka-Mrozik B, Stanik-Walentek A, Kapral M, et al: Differential expression of transforming growth factor-beta isoforms in bullous keratopathy corneas. Mol Vis. 16:161–166. 2010.PubMed/NCBI
24	Berezowski P, Strzalka-Mrozik B, Forminska-Kapuscik M, et al: Posttraumatic temporal TGF-beta mRNA expression in lens epithelial cells of paediatric patients. Folia Biol (Praha). 58:24–29. 2012.PubMed/NCBI
25	Kapral M, Wawszczyk J, Jurzak M, Hollek A and Weglarz L: The effect of inositol hexaphosphate on the expression of selected metalloproteinases and their tissue inhibitors in IL-1β-stimulated colon cancer cells. Int J Colorectal Dis. 27:1419–1428. 2012. View Article : Google Scholar : PubMed/NCBI
26	Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
27	Chen LY, Liu D and Songyang Z: Telomere maintenance through spatial control of telomeric proteins. Mol Cell Biol. 27:5898–5909. 2007. View Article : Google Scholar : PubMed/NCBI
28	Cong YS, Wright WE and Shay JW: Human telomerase and its regulation. Microbiol Mol Biol Rev. 66:407–425. 2002. View Article : Google Scholar : PubMed/NCBI
29	Ducrest AL, Szutorisz H, Lingner J and Nabholz M: Regulation of the human telomerase reverse transcriptase gene. Oncogene. 21:541–552. 2002. View Article : Google Scholar : PubMed/NCBI
30	Xu L, Li S and Stohr BA: The role of telomere biology in cancer. Annu Rev Pathol. 8:49–78. 2013. View Article : Google Scholar : PubMed/NCBI
31	Kibe T, Osawa GA, Keegan CE and de Lange T: Telomere protection by TPP1 is mediated by POT1a and POT1b. Mol Cell Biol. 30:1059–1066. 2010. View Article : Google Scholar : PubMed/NCBI
32	Xin H, Liu D, Wan M, et al: TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase. Nature. 445:559–562. 2007. View Article : Google Scholar : PubMed/NCBI
33	Zhong FL, Batista LF, Freund A, Pech MF, Venteicher AS and Artandi SE: TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends. Cell. 150:481–494. 2012. View Article : Google Scholar : PubMed/NCBI
34	Tejera AM Stagno, d'Alcontres M, Thanasoula M, et al: TPP1 is required for TERT recruitment, telomere elongation during nuclear reprogramming and normal skin development in mice. Dev Cell. 18:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
35	Chen LY, Redon S and Lingner J: The human CST complex is a terminator of telomerase activity. Nature. 488:540–544. 2012. View Article : Google Scholar : PubMed/NCBI
36	Nakashima M, Nandakumar J, Sullivan KD, Espinosa JM and Cech TR: Inhibition of telomerase recruitment and cancer cell death. J Biol Chem. 288:33171–33180. 2013. View Article : Google Scholar : PubMed/NCBI
37	Yang L, Wang W, Hu L, et al: Telomere-binding protein TPP1 modulates telomere homeostasis and confers radioresistance to human colorectal cancer cells. PLoS One. 8:e810342013. View Article : Google Scholar : PubMed/NCBI
38	Augereau A, de T'Kint Roodenbeke C, Simonet T, et al: Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation. Blood. 118:1316–1322. 2011. View Article : Google Scholar : PubMed/NCBI
39	Buell JF, Gross TG and Woodle ES: Malignancy after transplantation. Transplantation. 80(2 Suppl): S254–S264. 2005. View Article : Google Scholar : PubMed/NCBI
40	Herman M, Weinstein T, Korzets A, et al: Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med. 137:14–20. 2001. View Article : Google Scholar : PubMed/NCBI
41	Hojo M, Morimoto T, Maluccio M, et al: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 397:530–534. 1999. View Article : Google Scholar : PubMed/NCBI
42	Shihab FS, Bennett WM, Isaac J, Yi H and Andoh TF: Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity. Kidney Int. 63:522–533. 2003. View Article : Google Scholar : PubMed/NCBI
43	Koehl GE, Andrassy J, Guba M, et al: Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation. 77:1319–1326. 2004. View Article : Google Scholar : PubMed/NCBI
44	Dharnidharka VR, Ho PL, Stablein DM, Harmon WE and Tejani AH: Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant. 6:396–399. 2002. View Article : Google Scholar : PubMed/NCBI
45	Ohsugi Y, Suzuki S and Takagaki Y: Antitumor and immunosuppressive effects of mycophenolic acid derivatives. Cancer Res. 36:2923–2927. 1976.PubMed/NCBI
46	Carter SB, Franklin TJ, Jones DF, et al: Mycophenolic acid: an anti-cancer compound with unusual properties. Nature. 223:848–850. 1969. View Article : Google Scholar : PubMed/NCBI
47	Engl T, Makarević J, Relja B, et al: Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: Impact on tumor recurrence and malignancy. BMC Cancer. 5:42005. View Article : Google Scholar : PubMed/NCBI
48	Leckel K, Beecken WD, Jonas D, et al: The immunosuppressive drug mycophenolate mofetil impairs the adhesion capacity of gastrointestinal tumour cells. Clin Exp Immunol. 134:238–245. 2003. View Article : Google Scholar : PubMed/NCBI